Clinical Trial Update: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) [Phase 3]

View source ↗

Summary

A Phase 3 safety, tolerability and efficacy study of Veligrotug (VRDN 001) in healthy volunteers and Thyroid Eye Disease patients (THRIVE) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• Veligrotug (VRDN 001)

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED